X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (35) 35
index medicus (25) 25
tranexamic acid (23) 23
anti-fibrinolytics (14) 14
surgery (14) 14
aprotinin (13) 13
female (13) 13
animals (12) 12
anti-fibrinolytic (12) 12
hematology (12) 12
antifibrinolytic agents - therapeutic use (11) 11
male (11) 11
anti-fibrinolytic agents (10) 10
anti-fibrinolytic therapy (10) 10
aged (9) 9
transfusion (9) 9
adult (8) 8
anti-fibrinolytic agent (8) 8
cardiac surgery (8) 8
coagulation (8) 8
hemorrhage (8) 8
hemostasis (8) 8
medicine & public health (8) 8
middle aged (8) 8
bleeding (7) 7
cardiopulmonary bypass (7) 7
clinical neurology (7) 7
cooperative aneurysm (7) 7
fibrin (7) 7
health aspects (7) 7
subarachnoid hemorrhage (7) 7
anesthesiology (6) 6
antifibrinolytics (6) 6
care and treatment (6) 6
epsilon-aminocaproic acid (6) 6
risk factors (6) 6
tranexamic acid - therapeutic use (6) 6
aminocaproic acid (5) 5
antifibrinolytic agents - administration & dosage (5) 5
antifibrinolytic agents - adverse effects (5) 5
cardiac-surgery (5) 5
cerebral oximetry (5) 5
diagnosis (5) 5
pharmacology & pharmacy (5) 5
postpartum haemorrhage (5) 5
recombinant factor viia (5) 5
respiratory system (5) 5
thrombin (5) 5
blood-loss (4) 4
cancer (4) 4
cardiac & cardiovascular systems (4) 4
desmopressin (4) 4
factor viii inhibitors (4) 4
fibrinogen (4) 4
haemophilia a (4) 4
mice (4) 4
mortality (4) 4
oncology (4) 4
prevention (4) 4
prospective studies (4) 4
ruptured intracranial aneurysms (4) 4
time factors (4) 4
tranexamic acid - administration & dosage (4) 4
acquired deficiency (3) 3
activated factor-vii (3) 3
acute hydrocephalus (3) 3
acute normovolemic hemodilution (3) 3
adolescent (3) 3
aged, 80 and over (3) 3
aminocaproic acid - therapeutic use (3) 3
analysis (3) 3
anesthesia & perioperative care (3) 3
anti-fibrinolytic drugs (3) 3
anti-fibrinolytic potency (3) 3
anti-fibrinolytic response (3) 3
antifibrinolytic agents (3) 3
antifibrinolytic therapy (3) 3
antisaccadic eye movement test (3) 3
anti‐fibrinolytic agents (3) 3
autoantibodies (3) 3
bleeding disorder (3) 3
blood (3) 3
blood clots (3) 3
blood loss, surgical - prevention & control (3) 3
cardiac index (3) 3
cardiac surgical procedures - adverse effects (3) 3
caudal dexmedetomidine (3) 3
chemotherapy (3) 3
clot-lysis test (3) 3
cognitive dysfunction (3) 3
coronary artery bypass grafting (3) 3
coronary artery disease (3) 3
cystic-fibrosis (3) 3
diseases of the circulatory system (3) 3
efficacy (3) 3
fibrinolysis (3) 3
fibrinolysis - drug effects (3) 3
fibrinolytic agents - adverse effects (3) 3
fresh-frozen plasma (3) 3
hemophilia (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Laryngoscope, ISSN 0023-852X, 10/2013, Volume 123, Issue 10, pp. 2449 - 2452
Objectives/Hypothesis Symptomatic bleeding among patients with advanced upper aerodigestive tract tumor is a challenging problem. Given the limited options for... 
anti‐fibrinolytic | cancer | Bleeding | hemorrhage
Journal Article
Saudi Journal of Ophthalmology, ISSN 1319-4534, 05/2019
Journal Article
Pulmonary Pharmacology & Therapeutics, ISSN 1094-5539, 02/2020, Volume 60, p. 101871
Bronchoscopy is an essential therapeutic modality in the treatment of pulmonary bleeding. Although numerous endoscopic treatments exist, topical ε-aminocaproic... 
Bronchoscopy | Pulmonary bleeding | Anti-fibrinolytic | Hemoptysis | Aminocaproic acid | Hemostasis | TRANEXAMIC ACID | SURGERY | HEMORRHAGE | RESPIRATORY SYSTEM | PHARMACOLOGY & PHARMACY | MASSIVE HEMOPTYSIS
Journal Article
Journal of Drug Delivery Science and Technology, ISSN 1773-2247, 08/2019, Volume 52, pp. 559 - 567
The work reports fabrication of hemostatic patches containing an antifibrinolytic agent with an antibacterial, hemostat polymer. Membranes were fabricated by... 
Electrospinning | Tranexamic acid | Anti-fibrinolytic | Nanofiber | Chitosan | Hemostasis | SURGERY | BEHAVIOR | INJURY | RELEASE | HEMOSTATIC MATERIALS | FIBERS | PHARMACOLOGY & PHARMACY | FABRICATION | MORPHOLOGY
Journal Article
Best Practice & Research Clinical Obstetrics & Gynaecology, ISSN 1521-6934, 11/2019, Volume 61, pp. 66 - 74
Tranexamic acid reduces bleeding by inhibiting the breakdown of blood clots. It is cost-effective and heat-stable with a long shelf life. In the WOMAN trial,... 
Postpartum haemorrhage | Tranexamic acid | Anti-Fibrinolytic agents | Haemostasis | Fibrinolysis | Maternal health | CRASH-2 | DEATH | WOMAN | PREGNANCY | OBSTETRICS & GYNECOLOGY | WOMEN | TRAUMA PATIENTS | Pregnancy | Antifibrinolytic Agents - therapeutic use | Parturition | Humans | Postpartum Hemorrhage - drug therapy | Female | Postpartum Period | Tranexamic Acid - therapeutic use
Journal Article
Journal Article
Journal Article
Open Urology and Nephrology Journal, ISSN 1874-303X, 2018, Volume 11, Issue 1, pp. 79 - 86
Tranexamic acid has been shown to be an effective agent in reducing blood loss in various surgical procedures; however, there is a dearth of evidence for its... 
Surgical bleeding | Tranexamic acid | Anti-fibrinolytic | Transfusion rate | Urological surgery | Blood loss
Journal Article
Journal Article
Seminars in Pediatric Surgery, ISSN 1055-8586, 2014, Volume 24, Issue 1, pp. 17 - 19
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 2010, Volume 103, Issue 3, pp. 507 - 515
Summary Recently we prepared sulfated, low-molecular-weight lignins (LMWLs) to mimic the biological activities of heparin and heparan sulfate.... 
Theme Issue Article | Anti-fibrinolytic agent | Enzyme inhibition | Allostery | Anticoagulant | Heparin mimetics | Plasmin | Lignins | lignins | CRYSTAL-STRUCTURE | heparin mimetics | FIBRIN | enzyme inhibition | anti-coagulant | anti-fibrinolytic agent | ANTITHROMBIN | PERIPHERAL VASCULAR DISEASE | HEPARAN-SULFATE | HEMATOLOGY | BINDING | allostery | anticoagulant
Journal Article
Journal Article